MedTrace Logo

Colchicine in Periprocedural Myocardial Infarction: the Role of Alpha Defensin

NCT03735134 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2018-11-08

No results posted yet for this study

Summary

The aim of this research is to study the effect of a loading dose of colchicine on the occurrence of periprocedural myocardial infarction (PPMI) in elective percutaneous coronary intervention.

Conditions

Interventions

DRUG

Colchicine Loading Dose

Two milligrams of colchicine will be administrated in addition to the standard of care treatment

DRUG

Standard of care treatment prior to elective PCI

All medications normally given to patients prior to elective PCI

Sponsors & Collaborators

  • Hillel Yaffe Medical Center

    lead OTHER_GOV

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-30
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03735134 on ClinicalTrials.gov